20 completed, 4 withdrawn, 2 recruiting, 2 terminated. 30 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 20, Withdrawn 4, Recruiting 2, Terminated 2, Unknown 2 |
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Dutasteride: new trials by email Literature Review of Dutasteride trials Research Report on Dutasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer Dutasteride (0.5mg) - Bladder Cancer | Phase 2 | Recruiting | Paul Toren | 95 | 2026-03-25 | 2026-03-30 |
| Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) Dutasteride, Abiraterone - Prostate Cancer | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2023-02-01 | 2023-02-27 | |
| Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia. Dutasteride, Placebo - Male Androgenetic Alopecia | Phase 2 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 45 | 2022-09-29 | 2024-09-19 |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg - Salivary Duct Carcinoma | Phase 2 | Recruiting | Radboud University Medical Center | 26 | 2022-09-27 | 2025-06-04 |
| EAT-DUTA AndroCoV Trial Dutasteride 0.5 mg, Azithromycin, Nitazoxanide - Covid19 | Phase 2 / Phase 3 | Completed | Corpometria Institute | 138 | 2020-06-30 | 2021-01-28 |
| Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Dutasteride Capsules, Placebo Capsules - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | UConn Health | 180 | 2019-10-15 | 2025-05-09 |
| ITT-5 Mechanisms of Spermatogenesis in Man Testosterone 1% Gel, Acyline, Dutasteride - Gonadotropin Deficiency | Phase 2 | Withdrawn | University of Washington | 2019-06-01 | 2019-12-18 | |
| Role of Dutasteride in Treatment of Chronic Prostatitis Dutasteride 0.5 mg, Placebo - Dutasteride, Category IIIB Chronic Prostatitis | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2019-01-01 | 2021-02-16 |
| Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. Enzalutamide and Dutasteride or finasteride - Prostate Cancer | Phase 2 | Completed | University of Rochester | 43 | 2014-09-01 | 2024-11-13 |
| A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Enzalutamide, Abiraterone acetate, Prednisone - Prostate Cancer, Localized Prostate Cancer | Phase 2 | Withdrawn | Kenneth Pienta, MD | 2014-09-01 | 2015-01-26 | |
| Finasteride, Dutasteride and Insulin Action Finasteride, Dutasteride - Healthy Volunteers | Phase 2 | Unknown | University of Birmingham | 12 | 2012-08-01 | 2013-08-14 |
| Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Enzalutamide, Leuprolide, Dutasteride - Prostate Cancer | Phase 2 | Completed | Pfizer | 52 | 2012-03-31 | 2018-10-23 |
| Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Abiraterone acetate, Dutasteride, Prednisone - Prostate Cancer | Phase 2 | Completed | Mary-Ellen Taplin, MD | 40 | 2011-09-01 | 2018-03-15 |
| STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling STA9090, STA9090 with Dutasteride - Adenocarcinoma of the Prostate | Phase 2 | Withdrawn | Toni Choueiri, MD | 2011-04-01 | 2015-09-01 | |
| ITT4 Intratesticular Hormonal Milieu in Man (ITT4) Acyline, Testosterone gel, ketoconazole 400 - Healthy Males | Phase 1 / Phase 2 | Completed | University of Washington | 46 | 2011-01-01 | 2014-03-31 |
| Dutasteride in Treating Patients With Prostate Cancer dutasteride, gadolinium-chelate, active surveillance - Prostate Cancer | Phase 2 | Unknown | University College London Hospitals | 42 | 2010-06-01 | 2013-08-26 |
| Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer ketoconazole, hydrocortisone, dutasteride - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 11 | 2009-09-29 | 2018-09-04 |
| Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer Dutasteride, Placebo - Prostate Cancer | Phase 2 | Terminated | University of Colorado, Denver | 16 | 2009-09-01 | 2016-05-17 |
| Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy administration of a LHRH agonist and Bicalutamide, administration of Bicalutamide, Dutasteride and Tamoxifen - Prostate Cancer, Erectile Dysfunction | Phase 2 | Completed | CHU de Quebec-Universite Laval | 60 | 2009-03-01 | 2023-06-02 |
| PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA) - Healthy | Phase 2 / Phase 3 | Completed | University of Washington | 32 | 2009-01-01 | 2013-11-15 |
Showing 20 of 30. Sign in to see all of them.
Prostatic Neoplasms (15) · Hypogonadism (2) · Alcoholism (1) · Bulbo-Spinal Atrophy, X-Linked (1) · COVID-19 (1) · Erectile Dysfunction (1) · Lower Urinary Tract Symptoms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Hyperplasia (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
University of Washington (6) · GlaxoSmithKline (2) · Ain Shams University (1) · Beth Israel Deaconess Medical Center (1) · CHU de Quebec-Universite Laval (1) · Canadian Urology Research Consortium (1) · Corpometria Institute (1) · Dana-Farber Cancer Institute (1) · Endeavor Health (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) · Kenneth Pienta, MD (1) · Mary-Ellen Taplin, MD (1) · Masonic Cancer Center, University of Minnesota (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Paul Toren (1)
United States (18) · Canada (5) · United Kingdom (3) · Netherlands (2) · Spain (2) · Brazil (1) · Egypt (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Russia (1) · Sweden (1)
William J Bremner, MD, PhD (2) · Al Barqawi, MD (1) · Andre-Guy Martin, MD (1) · Andy Goren, MD (1) · Carlos G. Wambier, MD, Ph.D. (1) · Charles Ryan, MD (1) · Chunkit Fung, M.D. (1) · Daniel H Shevrin, MD (1) · Flavio A. Cadegiani, MD, MSc, Ph.D. (1) · Glenn Bubley, MD (1) · James L. Mohler, MD (1) · John K Amory, MD, MPH (1) · Jonathan Covault, MD, PhD (1)
PMID 18046048, PMID 18077826, PMID 19091347, PMID 19846582, PMID 21216197, PMID 23176897, PMID 23348398, PMID 23533230, PMID 23851165, PMID 24323034, PMID 24876969, PMID 25091040, PMID 25320358, PMID 27683182, PMID 32134978, PMID 36570649
K23HD045386 (2), P50AA027055 (1), U54HD012629 (1), U54HD042454 (1)